PopulationsHumans

Combined associations of GLP-1 medications and healthy lifestyle with cardiovascular outcomes among individuals with diabetes: The Million Veteran Program

AHA Scientific Sessions 2025 Abstract

The paper

Xuan‐Mai T. Nguyen, Yanping Li, Sébastien Czernichow,

Nathalie Rassy, Serena C. Houghton, Bing Lü, Yuk-Lam Anne Ho, Brian R. Charest, Dong Wang, David R. Gagnon, Michael Gaziano, Walter Churchill Willett, Peter W.F. Wilson, Kelly N. Kim,

VA Boston Healthcare System · Harvard University

AHA Scientific Sessions 2025 Abstract · 3 Nov 2025

Presented at AHA Scientific Sessions 2025 · Abstract 4362202

doi.org/10.1161/circ.152.suppl_3.4362202

SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
Diabetes drug class linked to slightly less frailty progression
Diabetes, Obesity & Metabolism · 8 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026